Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Chinn SB, Myers JN. Oral cavity carcinoma: current management, controversies, and future directions. J Clin Oncol. 2015;33:3269–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Divi V, Chen MM, Nussenbaum B, Rhoads KF, Sirjani DB, Holsinger FC, et al. Lymph node count from neck dissection predicts mortality in head and neck cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:3892–7.

Article  Google Scholar 

Daly ME, Le Q-T, Kozak MM, Maxim PG, Murphy JD, Hsu A, et al. Intensity-modulated radiotherapy for oral cavity squamous cell carcinoma: patterns of failure and predictors of local control. Int J Radiat Oncol. 2011;80:1412–22.

Article  Google Scholar 

Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre J-L, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.

Article  CAS  PubMed  Google Scholar 

Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.

Article  PubMed  Google Scholar 

Fan K-H, Lin C-Y, Kang C-J, Lee L-Y, Huang S-F, Liao C-T, et al. Postoperative concomitant chemoradiotherapy improved treatment outcomes of patients with oral cavity cancer with multiple-node metastases but no other major risk factors. PLoS One. 2014;9:e86922.

Article  PubMed  PubMed Central  Google Scholar 

Zumsteg ZS, Luu M, Kim S, Tighiouart M, Mita A, Scher KS, et al. Quantitative lymph node burden as a ‘very-high-risk’ factor identifying head and neck cancer patients benefiting from postoperative chemoradiation. Ann Oncol. 2019;30:76–84.

Article  CAS  PubMed  Google Scholar 

Lu DJ, Luu M, Gay C, Nguyen AT, Anderson EM, Bernier J, et al. Nodal metastasis count and oncologic outcomes in head and neck cancer: a secondary analysis of NRG/RTOG 9501, NRG/RTOG 0234, and EORTC 22931. Int J Radiat Oncol Biol Phys. 2022;113:787–95.

Article  PubMed  PubMed Central  Google Scholar 

Ang KK, Chen A, Curran WJ, Garden AS, Harari PM, Murphy BA, et al. Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN). Cancer. 2012;118:5783–92.

Article  PubMed  Google Scholar 

Lee JH, Song JH, Lee SN, Kang JH, Kim MS, Sun DI, et al. Adjuvant postoperative radiotherapy with or without chemotherapy for locally advanced squamous cell carcinoma of the head and neck: the importance of patient selection for the postoperative chemoradiotherapy. Cancer Res Treat Off J Korean Cancer Assoc. 2013;45:31–9.

Google Scholar 

Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel : recent developments. Clin Pharmacokinet. 2006;45:235–52.

Article  CAS  PubMed  Google Scholar 

Mason KA, Kishi K, Hunter N, Buchmiller L, Akimoto T, Komaki R, et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res Off J Am Assoc Cancer Res. 1999;5:4191–8.

CAS  Google Scholar 

Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res. 1996;56:1842–50.

CAS  PubMed  Google Scholar 

Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:2486–95.

Article  CAS  Google Scholar 

Fujii M, Tsukuda M, Satake B, Kubota A, Kida A, Kohno N, et al. Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol. 2004;9:107–12.

Article  CAS  PubMed  Google Scholar 

Rajesh I, Rajesh B, Selvamani B, John S. Feasibility and response of concurrent weekly docetaxel with radical radiotherapy in locally advanced head and neck squamous cell carcinoma. J Clin Diagn Res. 2015;9:XC01-4.

Google Scholar 

Patil VM, Noronha V, Menon N, Singh A, Ghosh-Laskar S, Budrukkar A, et al. Results of phase III randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation. J Clin Oncol. 2023;41:2350–61.

Article  CAS  PubMed  Google Scholar 

Li R, Jiang W, Dou S, Zhong L, Sun J, Zhang C, et al. A phase 2 trial of chemoradiation therapy using weekly docetaxel for high-risk postoperative oral squamous cell carcinoma patients. Int J Radiat Oncol Biol Phys. 2020;107:462–8.

Article  PubMed  Google Scholar 

Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: driving personalized medicine. Pharmacol Rev. 2023;75:789–814.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gu Z, Yao Y, Yang G, Zhu G, Tian Z, Wang R, et al. Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy. Sci Transl Med. 2022;14:eabo5987.

Article  CAS  PubMed  Google Scholar 

Barkan D, Chambers AF. β1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:7219–23.

Article  CAS  Google Scholar 

Legate KR, Wickström SA, Fässler R. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev. 2009;23:397–418.

Article  CAS  PubMed  Google Scholar 

Huttenlocher A, Horwitz AR. Integrins in cell migration. Cold Spring Harb Perspect Biol. 2011;3:a005074.

Article  PubMed  PubMed Central  Google Scholar 

Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics. 1988;44:229–41.

Article  CAS  PubMed  Google Scholar 

Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27:843–50.

Article  PubMed  Google Scholar 

Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head & neck. Int J Radiat Oncol Biol Phys. 2012;84:1198–205.

Article  PubMed  PubMed Central  Google Scholar 

Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:873–98.

Article  PubMed  Google Scholar 

Machiels J-P, René Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2020;31:1462–75.

Article  Google Scholar 

Kiyota N, Tahara M, Mizusawa J, Kodaira T, Fujii H, Yamazaki T, et al. Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II/III randomized controlled trial. J Clin Oncol. 2022;40:1980–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alterio D. Modern radiotherapy for head and neck cancer. Semin Oncol. 2019;46(3):233–45.

Article  CAS  PubMed  Google Scholar 

Leoncini E, Vukovic V, Cadoni G, Pastorino R, Arzani D, Bosetti C, et al. Clinical features and prognostic